New drug trial aims to tame autoimmune attack in Sjögren's disease
NCT ID NCT07404865
Summary
This study is testing whether an investigational drug called telitacicept can better control the symptoms of active primary Sjögren's disease compared to a placebo. It will involve about 250 adult participants who have the disease and will track changes in their symptoms, fatigue, and gland function over 48 weeks. The drug works by targeting specific immune system signals to reduce the harmful activity of B cells, which are thought to drive the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY SJOGREN'S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Accurate Clinical Research, Inc.
RECRUITINGLake Charles, Louisiana, 70605, United States
-
Accurate Clinical Research, Inc.
RECRUITINGHouston, Texas, 77089, United States
-
Chicago Clinical Research Institute Inc
RECRUITINGChicago, Illinois, 60607, United States
-
Novel Research LLC
RECRUITINGBellaire, Texas, 77401, United States
-
Velocity Clinical Research, Waco
RECRUITINGWaco, Texas, 76710, United States
Conditions
Explore the condition pages connected to this study.